Lbp Am Sa Has $105.84 Million Stake in Thermo Fisher Scientific Inc. $TMO

Lbp Am Sa raised its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 13.4% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 261,038 shares of the medical research company’s stock after purchasing an additional 30,837 shares during the period. Thermo Fisher Scientific accounts for approximately 1.5% of Lbp Am Sa’s investment portfolio, making the stock its 12th biggest position. Lbp Am Sa owned approximately 0.07% of Thermo Fisher Scientific worth $105,840,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in the business. CBIZ Investment Advisory Services LLC increased its position in Thermo Fisher Scientific by 137.5% in the 1st quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company’s stock valued at $28,000 after buying an additional 33 shares in the last quarter. Anderson Financial Strategies LLC purchased a new position in shares of Thermo Fisher Scientific in the 1st quarter worth approximately $30,000. Keystone Global Partners LLC bought a new stake in shares of Thermo Fisher Scientific in the 1st quarter worth approximately $31,000. IMA Advisory Services Inc. bought a new position in Thermo Fisher Scientific during the first quarter valued at $35,000. Finally, Smallwood Wealth Investment Management LLC bought a new position in shares of Thermo Fisher Scientific in the first quarter worth $37,000. 89.23% of the stock is owned by institutional investors.

Insider Activity

In other news, CAO Joseph R. Holmes sold 385 shares of the firm’s stock in a transaction dated Friday, August 29th. The stock was sold at an average price of $492.63, for a total transaction of $189,662.55. Following the completion of the transaction, the chief accounting officer owned 2,319 shares in the company, valued at $1,142,408.97. This trade represents a 14.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $479.98, for a total value of $191,992.00. Following the completion of the transaction, the executive vice president owned 22,367 shares of the company’s stock, valued at approximately $10,735,712.66. This represents a 1.76% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 30,066 shares of company stock worth $14,182,963 over the last 90 days. Corporate insiders own 0.33% of the company’s stock.

Wall Street Analysts Forecast Growth

TMO has been the subject of a number of analyst reports. Robert W. Baird raised their price target on Thermo Fisher Scientific from $553.00 to $567.00 and gave the stock an “outperform” rating in a report on Thursday, July 24th. HSBC reiterated a “hold” rating and issued a $510.00 price objective on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Scotiabank upgraded Thermo Fisher Scientific from a “sector perform” rating to a “sector outperform” rating and set a $590.00 price target on the stock in a report on Friday, July 11th. UBS Group upped their target price on Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a “neutral” rating in a report on Thursday, July 24th. Finally, William Blair began coverage on Thermo Fisher Scientific in a research report on Monday, August 18th. They issued an “outperform” rating on the stock. Fifteen equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $583.53.

Thermo Fisher Scientific Price Performance

NYSE:TMO opened at $484.70 on Wednesday. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65. The business’s 50-day simple moving average is $478.98 and its two-hundred day simple moving average is $446.98. The stock has a market cap of $183.03 billion, a PE ratio of 28.03, a P/E/G ratio of 2.51 and a beta of 0.75. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $620.00.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, beating analysts’ consensus estimates of $5.22 by $0.14. The business had revenue of $10.86 billion for the quarter, compared to analysts’ expectations of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The business’s quarterly revenue was up 2.9% on a year-over-year basis. During the same period last year, the firm earned $5.37 earnings per share. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be given a dividend of $0.43 per share. The ex-dividend date is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.4%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 9.95%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.